Registered title, quoted from ClinicalTrials.gov
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06754930, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Pathologically diagnosed NSCLC.
Inclusion criterion 5
Have undergone major surgery other than diagnosis or biopsy within 28 days prior to the initial dosing; Minor traumatic surgery within 7 days prior to the first dosing.
Exclusion criterion 5
Received other investigational drugs treatments 4 weeks prior to the initiation of the study treatment.
Exclusion criterion 6
Unresolved CTCAE 5.0>grade 2 toxicities from previous anticancer therapy.
Exclusion criterion 7
Eastern Cooperative Oncology Group (ECOG) score: 0-1.
Inclusion criterion 3
At least one measurable lesion according to RECIST v1.1.
Inclusion criterion 7
Contraception is required during clinical trials, and pregnancy tests must be negative for women of childbearing age within 7 days before the first dose.
Inclusion criterion 9
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06754930, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntary participation and written informed consent.
- 18-75 years older, no gender limitation.
- Eastern Cooperative Oncology Group (ECOG) score: 0-1.
- With a life expectancy ≥ 3 months.
- Pathologically diagnosed NSCLC.
- Be able to provide fresh or archived tumour tissue.
- At least one measurable lesion according to RECIST v1.1.
- Adequate organ function.
- Contraception is required during clinical trials, and pregnancy tests must be negative for women of childbearing age within 7 days before the first dose.
Exclusion Criteria:
- Meningeal metastasis history or clinical symptoms of central nervous system metastasis.
- Previous or co-existing malignancies.
- Spinal cord compression that was not treated radically by surgery and/or radiotherapy was excluded.
- Uncontrollable tumor-related pain.
- Have undergone major surgery other than diagnosis or biopsy within 28 days prior to the initial dosing; Minor traumatic surgery within 7 days prior to the first dosing.
- Received other investigational drugs treatments 4 weeks prior to the initiation of the study treatment.
- Unresolved CTCAE 5.0>grade 2 toxicities from previous anticancer therapy.
- With poorly controlled or severe cardiovascular disease.
- Active hepatitis B and hepatitis C.
- Patients with a history of immunodeficiency.
- Severe infection 30 days before the first dose.
Quoted from ClinicalTrials.gov, NCT06754930, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06754930, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.